## No. 1134

## Investigation of Pathophysiological Role of Novel Interacting Molecule with Angiotensin II Receptor in Salt Sensitive Hypertension

Kouichi Tamura<sup>1</sup>, Hiromichi Wakui<sup>2</sup>, Toru Dejima<sup>1</sup>, Masato Ohsawa<sup>1</sup>, Akinobu Maeda<sup>1</sup>, Satoshi Umemura<sup>1</sup>

<sup>1</sup> Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, <sup>2</sup> Yokohama City University Hospital

## Summary

We have been shown that ATRAP (angiotensin II type 1 receptor-associated protein) interacts with the angiotensin II type 1 receptor and promotes constitutive internalization of the angiotensin II type 1 receptor so as to inhibit its downstream signaling. The present study was designed to investigate the putatively beneficial role of renal ATRAP in angiotensin II-dependent hypertension. We generated transgenic mice dominantly expressing ATRAP in the renal distal tubules. In the renal ATRAP transgenic mice compared with the wild-type mice, the development of high blood pressure in response to angiotensin II infusion was suppressed based on radiotelemetry, with a concomitant increase in urinary sodium excretion. The renal mRNA and protein inductions of the  $\alpha$ -subunit of the epithelial sodium channel ( $\alpha$ ENaC) by angiotensin II infusion were decreased in the renal ATRAP transgenic mice compared with the wild-type mice. Furthermore, overexpression of ATRAP by adenoviral gene transfer suppressed the angiotensin II-mediated increase in the expression of ATRAP in mouse distal convoluted tubule cells. These results demonstrate that kidney-dominant overexpression of ATRAP *in vivo* suppresses angiotensin II-dependent hypertension, thereby suggesting ATRAP is a target of interest in hypertension.